Evaluation of Hematological Changes in HIV Infected Pregnant Women After Receiving HAART at Debremarkos Hospital, Debremarkos, Ethiopia

Kassahun Dires
Department of Pharmacology, College of Medicine, Debreberhan University, Debreberhan, Ethiopia

Email address: kash2009@gmail.com

To cite this article:

Received: June 25, 2018; Accepted: July 7, 2018; Published: August 15, 2018

Abstract: Hematological complications are documented as the second most common cause of morbidity and mortality in HIV/AIDS patients. Drugs for HIV/AIDS showed side effects on different hematological parameters. This study was aimed at assessing the changes in hematological profile of HIV infected pregnant women after initiation of highly active antiretroviral treatment. Retrospective cohort study was conducted to assess the hematological changes in HIV infected pregnant women after initiation of highly active antiretroviral (HAART) at ART clinic of Debremarkos hospital in Ethiopia from May to August 2017. Data available between May 2008 and August 2017 was collected from 380 patient cards of pregnant women. The data was entered into Excel spread sheet and was transported into STATA software for analysis. All data were presented as mean ± Standard error of the mean. Comparisons were made using the Paired T-test. A p-value of <0.05 was considered as a statistically significant difference. The result from the present study shows that the HAART initiation in pregnant women with HIV increases the CD4 cell count, the mean corpuscular hemoglobin concentration, white blood cell count, lymphocyte count and total mid cell count at ninety-five percent confidence interval. From the total of 380 patient cards with complete CD4 count, 200 patient cards were recorded with TDF/3TC/EFV ART regimen. The remaining 180 patient cards were documented with AZT/3TC/NVP regimen. Comparing the effect of the two Regimens on CD4 count, TDF/3TC/EFV increases the CD4 count significantly in pregnant women with HIV (p<0.0001). The other regimen (AZT/3TC/NVP) also increases the CD4 count from initial value but this increase in CD4 count after AZT/3TC/NVP initiation in pregnant women with HIV is not statistically significant (P>0.05). HAART initiation in pregnant women with HIV increases lymphocyte count, total mid cell count, red blood cell count, white blood cell count, total hemoglobin, hematocrit, mean cell volume and total platelet. On the contrary, the initial value of granulocyte count, mean cell hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width and mean platelet volume decreases after antiretroviral treatment in pregnant women with HIV.

Keywords: Hematological Parameters, HAART, HIV Positive Pregnant Women

1. Introduction

In 2014, 1.2 million people died from HIV-related causes globally. There were approximately 36.9 million people living with HIV at the end of 2014 with 2.0 million people becoming newly infected with HIV in 2014 globally, Sub-Saharan Africa, with 25.8 million people living with HIV in 2014. Also sub-Saharan Africa accounts for almost 70% of the global total of new HIV infections [1].

In Ethiopia, the 2014 estimated number of people living with HIV was 769,600 with 15,700 new HIV infections and 35,600 AIDS-related deaths [2]. HIV is characterized by progressive damage to the body’s immune system which results in the development of a number of opportunistic infections and other complications [3]. The most important biomarkers of disease stage and progression in patients with an HIV infection are the CD4 count and HIV RNA concentration [4]. However, there are other factors that can influence or predict the prognosis. Hematological abnormalities, such as anemia, neutropenia, and thrombocytopenia, are commonly observed in patients infected with HIV [5]. For this reason the total lymphocyte
count, white blood cell count, and hematocrit or hemoglobin concentration have been proposed as alternative markers of the disease, especially for developing countries where financial resources are limited [6].

The introduction of highly active antiretroviral therapy (HAART) has led to significant reduction in acquired immune deficiency syndrome (AIDS)-related morbidity and mortality. Adverse drug reactions (ADRs) to antiretroviral treatment (ART) are, however, major obstacles in its success [7]. The Centre for Disease Control (CDC) advocates that before the use of any anti-retroviral therapy, the safety and efficacy of the drug should be tested [8].

There are limited studies conducted on hematological changes in pregnant women after starting HAART regimen in developing countries especially in Ethiopia. This study, therefore, provide information about the change of hematological profile in pregnant women after HAART regimens which may contribute in improving the management of patients after initiation of Anti-retroviral treatment.

2. Materials and Methods

2.1. Study Design and Settings

Retrospective cohort study was conducted to assess hematological profile of HIV infected pregnant women after initiation of HAART at ART clinic of Debremarkos hospital in Ethiopia from May to August 2017. The type of ART regimen, hematological data (White blood cells, CD4+ T cells, hemoglobin, and Platelet count) and values for other hematological indices were carefully collected from 380 patient follow up cards that were available between May 2008 and August 2017.

2.2. Data Processing and Analysis

The data was entered into Excel spread sheet and it was transported into STATA software for analysis. All data were presented as mean ± Standard error of the mean. Comparisons were made using the Paired T-test. A p-value of <0.05 was considered to be statistically significant.

3. Result

HAART initiation in pregnant women with HIV increases lymphocyte count, total mid cell count, red blood cell count, white blood cell count, total hemoglobin, hematocrit, mean cell volume, and total platelet. On the contrary, the initial value of granulocyte count, mean cell hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width and mean platelet volume decreases after antiretroviral treatment in pregnant women with HIV.

Among a total of 380 pregnant women, two hundred patients were treated with TDF/3TC/EFV ART regimen and the remaining one hundred eighty received AZT/3TC/NVP (table 1, 2).

Table 1. Shows the number of patient cards taken for analysis for each hematological parameter.

<table>
<thead>
<tr>
<th>Hematological parameter</th>
<th>number</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 count</td>
<td>380</td>
</tr>
<tr>
<td>WBC count</td>
<td>380</td>
</tr>
<tr>
<td>Lymphocyte count</td>
<td>380</td>
</tr>
<tr>
<td>Total mid cell count</td>
<td>380</td>
</tr>
<tr>
<td>Granulocyte count</td>
<td>380</td>
</tr>
<tr>
<td>RBC count</td>
<td>380</td>
</tr>
<tr>
<td>Total haemoglobin</td>
<td>380</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>380</td>
</tr>
<tr>
<td>Mean cell volume</td>
<td>380</td>
</tr>
<tr>
<td>Mean cell hemoglobin</td>
<td>380</td>
</tr>
<tr>
<td>Mean cell hemoglobin concentration</td>
<td>380</td>
</tr>
<tr>
<td>Red cell distribution width coefficient of variation</td>
<td>380</td>
</tr>
<tr>
<td>Total platelet count</td>
<td>380</td>
</tr>
<tr>
<td>Mean platelet volume</td>
<td>380</td>
</tr>
<tr>
<td>PCT in percent</td>
<td>380</td>
</tr>
</tbody>
</table>

Table 2. Shows the number of study participants per treatment regimen.

<table>
<thead>
<tr>
<th>ART regimen</th>
<th>Number of patient cards per regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>number</td>
</tr>
<tr>
<td>TDF/3TC/EFV</td>
<td>200</td>
</tr>
<tr>
<td>AZT/3TC/NVP</td>
<td>180</td>
</tr>
<tr>
<td>total</td>
<td>380</td>
</tr>
</tbody>
</table>

Comparing the effect of the two Regimens on CD4 count, TDF/3TC/EFV increases significantly the CD4 count in pregnant women with HIV (p<0.0001). The other regimen (AZT/3TC/NVP) also increases the CD4 count from initial value as it is indicated by positive paired mean difference but this increase in CD4 count after AZT/3TC/NVP initiation in pregnant women with HIV is not statistically significant at 95 percent confidence interval (p>0.05, table 3).

Table 3. CD4 T-cell changes in pregnant women with HIV per treatment regimen.

<table>
<thead>
<tr>
<th>ART regimen</th>
<th>CD4 before</th>
<th>CD4 after</th>
<th>Paired mean difference</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF/3TC/EFV</td>
<td>400±28</td>
<td>600±47</td>
<td>200±19</td>
<td>P&lt;0.0001</td>
</tr>
<tr>
<td>AZT/3TC/NVP</td>
<td>370±20</td>
<td>378±25</td>
<td>8±5</td>
<td>P=0.05</td>
</tr>
</tbody>
</table>

Describing the effect on other hematological parameters, HAART initiation in pregnant women with HIV increases the value of lymphocyte count, total mid cell count, red blood cell count, white blood cell count, total hemoglobin, hematocrit, mean cell volume and total platelet. On the contrary, the initial value of granulocyte count, mean cell hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width and mean platelet volume decreases after antiretroviral treatment in pregnant women with HIV (p<0.05) (table 4).
pregnant women on highly active antiretroviral therapy in
there were no significant changes in Hb [12]. Another study
2013 to February, 2014 showed that in the first trimester
2013 by Cherish et al to assess the effect of triple zidovudine
and this finding is not in agreement with the current finding.
parameters is less than 0.5 when it is compared with the
indicated that ART brings statistically significant increment
in WBC from 4070±250 cells/µl at baseline to 4760±170
in WBC from 4070±250 cells/µl at baseline to 4760±170
cells/µl after antiretroviral drugs treatment [3]. The result of
which was sustained up to the sixth month of therapy [13].
This shows that the present finding concerning the effect on
platelet count and white blood cell count in pregnant women
after HAART is consistent with reports described above.

4. Discussion

In the present study, CD4 T-cell count was increased after
initiation of HAART. For those pregnant women who received TDF/3TC/NVP, the numbers of increased CD4 T-cells were 200±19 cells and for those who received AZT/3TC/NVP were 8±5 cells. This finding is comparable with other reports done somewhere else. A study conducted in India on AIDS patients showed that Mean baseline CD4+ T-cell count was 112±60 cells/µl. After treatment, a CD4 cell count increased by >50 cells/µl in 84.6% cases [9].

In this finding, RBC count, hematocrit and hemoglobin levels increased from the baseline data (P<0.05). An observational cohort study done in Tanzania in 2013 described that pregnant woman after receiving zidovudine containing regimen showed that RBC count decreased within the first four weeks HAART intake and then increased [10]. That final increment in RBC count after long term HAART intake in pregnant women is consistent with the current study. Another study showed that Red Blood Cell count (RBC) and Hematocrit (HCT) were significantly reduced compared to control subjects [11] to mean that this report is not consistent with the current study.

Another follow-up study carried out on some hematological and hem rheological changes in HIV-infected pregnant women on highly active antiretroviral therapy in University of Benin Teaching Hospital, Nigeria, from April 2013 to February, 2014 showed that in the first trimester there were no significant changes in Hb [12]. Another study also was done in Burkina Faso, Kenya and South Africa, 2013 by Cherish et al to assess the effect of triple zidovudine containing regimens, ART eligible pregnant women were followed from 28 weeks of pregnancy (n = 1070). At enrolment (corresponded to a median of 32 weeks gestation), the median hemoglobin was 10.3 g/dl. Severe anemia occurred subsequently in 194 (18.1%) of women. After 1–2 months of ARV’s, severe anemia was significantly reduced in all groups, though remained highest in the low CD4 cohort and this finding is not in agreement with the current finding.

5. Conclusion

In conclusion, HAART initiation in pregnant women with HIV increases lymphocyte count, total mid cell count, red blood cell count, white blood cell count, total hemoglobin, hematocrit, mean cell volume and total platelet. On the contrary, the initial value of, granulocyte count, mean cell hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width and mean platelet volume decreases after antiretroviral treatment in pregnant women with HIV.

4. Discussion

In the present study, CD4 T-cell count was increased after
initiation of HAART. For those pregnant women who received TDF/3TC/NVP, the numbers of increased CD4 T-cells were 200±19 cells and for those who received AZT/3TC/NVP were 8±5 cells. This finding is comparable with other reports done somewhere else. A study conducted in India on AIDS patients showed that Mean baseline CD4+ T-cell count was 112±60 cells/µl. After treatment, a CD4 cell count increased by >50 cells/µl in 84.6% cases [9].

In this finding, RBC count, hematocrit and hemoglobin levels increased from the baseline data (P<0.05). An observational cohort study done in Tanzania in 2013 described that pregnant woman after receiving zidovudine containing regimen showed that RBC count decreased within the first four weeks HAART intake and then increased [10]. That final increment in RBC count after long term HAART intake in pregnant women is consistent with the current study. Another study showed that Red Blood Cell count (RBC) and Hematocrit (HCT) were significantly reduced compared to control subjects [11] to mean that this report is not consistent with the current study.

Another follow-up study carried out on some hematological and hem rheological changes in HIV-infected pregnant women on highly active antiretroviral therapy in University of Benin Teaching Hospital, Nigeria, from April 2013 to February, 2014 showed that in the first trimester there were no significant changes in Hb [12]. Another study also was done in Burkina Faso, Kenya and South Africa, 2013 by Cherish et al to assess the effect of triple zidovudine containing regimens, ART eligible pregnant women were followed from 28 weeks of pregnancy (n = 1070). At enrolment (corresponded to a median of 32 weeks gestation), the median hemoglobin was 10.3 g/dl. Severe anemia occurred subsequently in 194 (18.1%) of women. After 1–2 months of ARV’s, severe anemia was significantly reduced in all groups, though remained highest in the low CD4 cohort and this finding is not in agreement with the current finding.

The current study shows that HAART initiation in pregnant women has significant effect on total platelet and white blood cell count as p-value for both hematological parameters is less than 0.5 when it is compared with the initial value. This is finding is not supported with a follow-up study carried out on some hematological and hem rheological changes in HIV-infected pregnant women on highly active antiretroviral therapy in University of Benin Teaching Hospital, Nigeria, from April 2013 to February, 2014 showed that in the first trimester there were no significant changes in WBC and WBV (P>0.05) between test and control subjects [12]. A Study conducted in Markurdi, Benue state of Nigeria indicated that ART brings statistically significant increment in WBC from 4070±250 cells/µl at baseline to 4760±170 cells/µl after antiretroviral drugs treatment [3]. The result of a study done in Italy indicated that HAART induced a significant increase in the PLT count within the third month which was sustained up to the sixth month of therapy [13]. This shows that the present finding concerning the effect on platelet count and white blood cell count in pregnant women after HAART is consistent with reports described above.

5. Conclusion

In conclusion, HAART initiation in pregnant women with HIV increases lymphocyte count, total mid cell count, red blood cell count, white blood cell count, total hemoglobin, hematocrit, mean cell volume and total platelet. On the contrary, the initial value of, granulocyte count, mean cell hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width and mean platelet volume decreases after antiretroviral treatment in pregnant women with HIV.

### Abbreviations and Acronyms

- **AIDS**: Acquired Immune Deficiency Syndrome
- **ART**: Anti Retroviral Therapy
- **AZT/ZDV**: Zidovudine
Acknowledgements

I would like to thank Mr. Nigus Zegeye for initiating me to conduct this research. Debremarkos Hospital patient card manager is also acknowledged for his cooperation during data collection.

Conflict of Interest

The authors declare that they have no competing interests.

Ethics Approval and Consent to Participate

Ethical clearance was obtained from the Ethics Review Committee of College of Medicine, Debreberhan University. Official letter was written to the head of the hospital to obtain permission to collect the data. Patient information obtained from patient cards was kept confidential.

References

[8] National Institute for Allergy and Infectious Disease (NIAID), Division of AIDS (2009). Table for grading the severity of adult and pediatric adverse events, version 1. 0 (2004), Clarification Augus 2009. Available at: http://rsc.tech-res